当前位置: 首页 > 期刊 > 《中国医学创新》 > 2024年第13期
编号:1972759
滤泡性淋巴瘤的治疗进展
http://www.100md.com 2024年6月21日 中国医学创新 2024年第13期
     初文慧 高娜 刘增艳 曹曰针 孙大伟 于文征

    【摘要】 滤泡性淋巴瘤(follicular lymphoma,FL)是最常见的惰性B细胞非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL),它是一种异质性疾病,其治疗方式多样,包括观察、放疗和全身治疗。但对于多数患者来说,在找到治疗指征之前观察仍然是最常见的治疗方法。早期FL患者的标准治疗方法是放疗,晚期或复发/难治性FL患者可以选择免疫化疗、靶向免疫治疗等。近年来,随着对FL发病机制的深入研究,新的药物和治疗方法也层出不穷,本文对FL的治疗进展做一综述。

    【关键词】 滤泡性淋巴瘤 免疫化疗 靶向免疫治疗

    Therapeutic Progress of Follicular Lymphoma/CHU Wenhui, GAO Na, LIU Zengyan, CAO Yuezhen, SUN Dawei, YU Wenzheng. //Medical Innovation of China, 2024, 21(13): -167

    [Abstract] Follicular lymphoma (FL) is the most common inert B-cell non-Hodgkin lymphoma (NHL). It is a heterogeneous disease, and its treatment methods are diverse, including observation, radiotherapy and systemic treatment. However, for most patients, observation is still the most common treatment method before finding the indications for treatment. The standard treatment for patients with early-stage FL is radiotherapy, while patients with late-stage or relapsed/refractory FL can choose immunochemotherapy, targeted immunotherapy, etc. In recent years, with the in-depth study of the pathogenesis of FL, new drugs and treatment methods are emerging in an endless stream. This article reviews the therapeutic progress of FL. ......

您现在查看是摘要页,全文长 23606 字符